Based on these findings and the high expression of GLUT-1 in tumors, we designed and synthesized new specific inhibitors of LDH-A [20] and GLUT-1 [21], aiming to specifically target the energy metabolism in cancer cells. The gene discussed is SLC2A1; the disease is cancer.